CD274 and neoplasm: Immunotherapy has opened a new era of tumor therapy, and immunocheckpoint inhibitors (ICIs), including programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1) inhibitors, have become a breakthrough in tumor therapy.